Compounds > anidulafungin
Page last updated: 2024-09-05

anidulafungin and Candidemia

anidulafungin has been researched along with Candidemia in 43 studies

Research

Studies (43)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's33 (76.74)24.3611
2020's10 (23.26)2.80

Authors

AuthorsStudies
Farooqi, J; Jabeen, K; Memon, S; Naqvi, SF; Zafar, A; Zafar, U1
Gonçalves, GA; Kraft, L; Ribeiro, VST; Suss, PH; Tuon, FF1
Mosegui, GBG; Rodrigues, MPDS; Vianna, CMM1
Abastabar, M; Badiee, P; Haghani, I; Mohammadi, R; Morovati, H; Noorbakhsh, M; Sharifi, M1
Corcione, S; D'Avolio, A; De Rosa, FG; Pagani, N; Pasero, D; Sanguinetti, M; Trentalange, A1
Aram, JA; Carlesse, F; Conte, U; Leister-Tebbe, H; Queiroz-Telles, F; Raber, S; Roilides, E; Swanson, R; Tawadrous, M; Yan, JL1
Davis, SL; Hutton, M; Kenney, RM; Vazquez, JA1
Kim, JH; Kim, MJ; Kim, SB; Sohn, JW; Suh, JW; Yoon, YK1
Bot, JCJ; de Leeuw, DC; Hendriks, EJ; Overgaauw, AJC; Stoof, SP; van Dijk, K1
An, MM; Chen, SM; Guo, SY; Hou, WT; Hu, XY; Jiang, YY; Qiu, XR; Shen, H; Song, LJ; Zhang, Y; Zou, Z1
Aram, JA; Busca, A; Capparella, MR; De Rosa, FG; Yan, JL1
Arthur, I; Baird, R; Bak, N; Blyth, C; Botes, J; Chapman, B; Chen, S; Cheong, E; Cooley, L; George, CR; Goeman, E; Hajkowicz, K; Halliday, C; Heath, CH; Hofmeyr, A; Kalukottege, P; Keighley, C; Kennedy, K; Kesson, A; Kidd, S; Korman, TM; Leung, M; Liu, E; Macesic, N; Marriott, D; McMullan, B; Morrissey, CO; Pendle, S; Robson, J; Slavin, M; Sorrell, TC; Underwood, N; van Hal, S; Weeks, K1
Agurto, C; Bustamante, B; Diaz, A; Hidalgo, J; Huaroto, L; Illescas, R; Ramirez, R; Rodriguez, L1
Aram, J; Bassetti, M; Capparella, MR; Hogan, PA; Kontoyiannis, DP; Nucci, M; Yan, JL1
Charbonneau, C; Chen, YC; Lee, TY; Ou, HT1
Graf, BM; Gruber, M; Ittner, KP; Kolbinger, P; Roth, G1
Arango, K; Berrio, I; Cano, LE; De Bedout, C; Gómez, BL; Jiménez-Ortigosa, C; Maldonado, N; Perlin, DS; Robledo, C; Robledo, J; Valencia, Y1
Chew, KL; Lin, RTP; Octavia, S; Teo, JWP; Yan, GZ1
Ataollahy, N; Hammarström, H; Kondori, N; Lindberg, E1
Katragkou, A; Kyrpitzi, D; Peshkova, P; Roilides, E; Simitsopoulou, M; Tasina, E; Velegraki, A; Walsh, TJ1
Co, VM; Hsueh, PR; Mootsikapun, P; Ong, ML; Rajadhyaksha, V; Talwar, D1
Barrueta, JA; Carlos Pozo Laderas, J; García Vargas, M; Grau, S; Mir, N; Salavert, M1
Baietto, L; Corcione, S; D'Avolio, A; De Rosa, FG; Di Perri, G; Pasero, D; Ranieri, VM1
Biswas, P; Chin-Hong, P; Kett, DH; Pappas, PG; Patterson, TF; Reboli, AC; Reinhardt, J; Swanson, R; Tobin, E; Vazquez, J1
Beldavs, ZG; Bolden, CB; Chiller, TM; Cleveland, AA; Farley, MM; Harrison, LH; Iqbal, N; Kuykendall, RJ; Lockhart, SR; Park, BJ; Pham, CD; Schaffner, W1
Cornely, OA; Franke, B; Glossmann, J; Heimann, SM; Kochanek, M; Langebartels, G; Padosch, SA; Reiner, M; Reuter, H; Seifert, H; Stippel, D; Vehreschild, JJ; Vehreschild, MJ; Vierzig, A; Wisplinghoff, H1
Doan, TN; Kirkpatrick, CM; Kong, DC; Patel, K; Spencer, A; Walker, P1
Auzinger, G; Charbonneau, C; Graham, CN; Kantecki, M; Knox, HN; Playford, EG; Schlamm, H; Weinstein, D1
Bouza, E; Escribano, P; Guinea, J; Marcos-Zambrano, LJ1
Ahmad, N; Ginsapu, SJ; Gowbei, A; Hashim, R; Ho Betty, LS; Ramli, NY; Razak, MF; Sabaratnam, P; Sipiczki, M; Suppiah, J; Tap, RM1
Calvo, B; Colombo, AL; Francisco, EC; Hagen, F; Hernandez, M; Meis, JF; Melo, AS; Perozo-Mena, A1
Hsueh, PR; Wang, H; Xu, YC1
Bouza, E; Escribano, P; Guinea, J; Marcos-Zambrano, LJ; Sánchez-Carrillo, C1
Aznar, J; de Toro, M; Maite, R; Torres, MJ1
Barre, O; Gay-Andrieu, F; Le Pape, P; Miegeville, M; Morio, F; Thierry, G1
De Rosa, FG; Falcone, M; Ghezzi, MC; Pasero, D; Raponi, G; Russo, A; Toma, L; Venditti, M1
Cartier, S; Chambers, R; Kett, DH; Maschio, M; Reboli, AC; Rotstein, C; Tarallo, M1
Bernhardt, H; Bernhardt, J; Knoke, M1
Bellmann, R; Gustorff, B; Hell, M; Illievich, U; Kratzer, C; Lass-Flörl, C; Moosbauer, W; Nachbaur, K; Perkhofer, S; Schwameis, F; Vogel, W; Von Goedecke, A; Wimmer, P; Zerlauth, U1
Biswas, P; Kett, DH; Reboli, AC; Reisman, AL; Schlamm, HT; Shorr, AF1
Jaijakul, S; Ostrosky-Zeichner, L; Swanson, RN; Vazquez, JA1
Liu, P1
Damle, B; Kantecki, M; Liu, P; Meersseman, W; Paiva, JA; Ruhnke, M1

Reviews

2 review(s) available for anidulafungin and Candidemia

ArticleYear
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies.
    Clinical drug investigation, 2021, Volume: 41, Issue:6

    Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Fluconazole; Humans; Neoplasms; Treatment Outcome; Voriconazole

2021
Epidemiology of candidemia and antifungal susceptibility in invasive Candida species in the Asia-Pacific region.
    Future microbiology, 2016, Volume: 11

    Topics: Anidulafungin; Antifungal Agents; Asia; Azoles; Candida; Candida albicans; Candida glabrata; Candida tropicalis; Candidemia; Candidiasis; Candidiasis, Invasive; Drug Resistance, Fungal; Echinocandins; Fluconazole; Humans; Incidence; Itraconazole; Lipopeptides; Micafungin; Microbial Sensitivity Tests; Phenotype; Prevalence; Voriconazole

2016

Trials

7 trial(s) available for anidulafungin and Candidemia

ArticleYear
Safety, Efficacy and Pharmacokinetics of Anidulafungin in Patients 1 Month to <2 Years of Age With Invasive Candidiasis, Including Candidemia.
    The Pediatric infectious disease journal, 2020, Volume: 39, Issue:4

    Topics: Administration, Intravenous; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Female; Humans; Infant; Infant, Newborn; Male; Prospective Studies; Treatment Outcome

2020
Anidulafungin for the treatment of candidaemia caused by Candida parapsilosis: Analysis of pooled data from six prospective clinical studies.
    Mycoses, 2017, Volume: 60, Issue:10

    Topics: Administration, Intravenous; Adult; Anidulafungin; Antifungal Agents; Azoles; Candida parapsilosis; Candidemia; Candidiasis, Invasive; Clinical Trials as Topic; Echinocandins; Female; Fluconazole; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Prospective Studies; Treatment Outcome

2017
Intravenous anidulafungin followed optionally by oral voriconazole for the treatment of candidemia in Asian patients: results from an open-label Phase III trial.
    BMC infectious diseases, 2013, May-15, Volume: 13

    Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adult; Aged; Anidulafungin; Antifungal Agents; Candidemia; Echinocandins; Female; Humans; Male; Middle Aged; Pyrimidines; Treatment Outcome; Triazoles; Voriconazole; Young Adult

2013
Evaluation of an early step-down strategy from intravenous anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial.
    BMC infectious diseases, 2014, Feb-21, Volume: 14

    Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Anidulafungin; Antifungal Agents; Candida; Candidemia; Candidiasis; Candidiasis, Invasive; Echinocandins; Female; Fluconazole; Humans; Male; Middle Aged; Republic of Korea; Research Design; Risk; Treatment Outcome; United States; Voriconazole; Young Adult

2014
Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis.
    Critical care (London, England), 2011, Volume: 15, Issue:5

    Topics: Aged; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Double-Blind Method; Echinocandins; Female; Fluconazole; Humans; Male; Middle Aged; Practice Guidelines as Topic; Prospective Studies; Severity of Illness Index; Societies, Medical; Treatment Outcome; United States

2011
(1,3)-β-D-glucan as a prognostic marker of treatment response in invasive candidiasis.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2012, Volume: 55, Issue:4

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anidulafungin; Antifungal Agents; beta-Glucans; Biomarkers; Candidemia; Candidiasis, Invasive; Echinocandins; Female; Humans; Male; Middle Aged; Proteoglycans; ROC Curve; Treatment Outcome

2012
Pharmacokinetics of anidulafungin in critically ill patients with candidemia/invasive candidiasis.
    Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:4

    Topics: Adult; Aged; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Critical Illness; Echinocandins; Female; Humans; Male; Middle Aged

2013

Other Studies

34 other study(ies) available for anidulafungin and Candidemia

ArticleYear
Antifungal susceptibility profile of invasive
    Journal of medical microbiology, 2021, Volume: 70, Issue:12

    Topics: Amphotericin B; Anidulafungin; Antifungal Agents; Candida glabrata; Candidemia; Caspofungin; Cross-Sectional Studies; Drug Resistance, Fungal; Fluconazole; Humans; Micafungin; Pakistan; Retrospective Studies; Tertiary Care Centers

2021
Comparison of amphotericin B lipid complex, deoxycholate amphotericin B, fluconazole, and anidulafungin activity against Candida albicans biofilm isolated from breakthrough candidemia.
    Enfermedades infecciosas y microbiologia clinica (English ed.), 2023, Volume: 41, Issue:10

    Topics: Amphotericin B; Anidulafungin; Antifungal Agents; Biofilms; Candida; Candida albicans; Candidemia; Deoxycholic Acid; Fluconazole; Humans

2023
Cost-effectiveness analysis and budgetary impact of anidulafungin treatment for patients with candidemia and other forms of invasive candidiasis in Brazil.
    Revista do Instituto de Medicina Tropical de Sao Paulo, 2023, Volume: 65

    Topics: Anidulafungin; Brazil; Candidemia; Candidiasis, Invasive; Cost-Effectiveness Analysis; Humans

2023
A 3-year study of
    Frontiers in cellular and infection microbiology, 2023, Volume: 13

    Topics: Amphotericin B; Anidulafungin; Antifungal Agents; Candida; Candidemia; Candidiasis; Drug Resistance, Fungal; Fluconazole; Humans; Itraconazole; Microbial Sensitivity Tests; Neoplasms

2023
Acquisition of FKS2 mutation after echinocandin treatment of infective endocarditis by Candida glabrata.
    Le infezioni in medicina, 2019, Sep-01, Volume: 27, Issue:3

    Topics: Aged; Anidulafungin; Antifungal Agents; Candida glabrata; Candidemia; Candidiasis; Endocarditis; Female; Fungal Proteins; Heart Valve Prosthesis Implantation; Humans; Microbial Sensitivity Tests; Point Mutation; Voriconazole

2019
Influence of Body Weight Category on Outcomes in Candidemia Patients Treated With Anidulafungin.
    Journal of pharmacy practice, 2022, Volume: 35, Issue:1

    Topics: Anidulafungin; Antifungal Agents; Candida; Candidemia; Humans; Obesity, Morbid; Retrospective Studies

2022
Anidulafungin Versus Micafungin in the Treatment of Candidemia in Adult Patients.
    Mycopathologia, 2020, Volume: 185, Issue:4

    Topics: Aged; Anidulafungin; Antifungal Agents; Candidemia; Echinocandins; Female; Humans; Lipopeptides; Male; Micafungin; Middle Aged; Retrospective Studies

2020
Case report: Candida krusei spondylitis in an immunocompromised patient.
    BMC infectious diseases, 2020, Oct-08, Volume: 20, Issue:1

    Topics: Aged; Anidulafungin; Antifungal Agents; Candida; Candidemia; Candidiasis; Humans; Immunocompromised Host; Induction Chemotherapy; Male; Micafungin; Spondylitis; Treatment Outcome; Voriconazole

2020
Preventing
    Emerging microbes & infections, 2020, Volume: 9, Issue:1

    Topics: Anidulafungin; Animals; Antibodies, Monoclonal; Antifungal Agents; Caco-2 Cells; Candida albicans; Candidemia; Disease Models, Animal; Drug Synergism; Endothelial Cells; Epithelial Cells; Female; Fluconazole; Fungal Proteins; Human Umbilical Vein Endothelial Cells; Humans; Mice; Phosphopyruvate Hydratase; Plasminogen; Protein Binding; Protein Structure, Secondary

2020
Changing epidemiology of candidaemia in Australia.
    The Journal of antimicrobial chemotherapy, 2017, 04-01, Volume: 72, Issue:4

    Topics: Anidulafungin; Antifungal Agents; Australia; Azoles; Candida; Candida glabrata; Candida tropicalis; Candidemia; Caspofungin; Drug Resistance, Fungal; Echinocandins; Female; Fluconazole; Humans; Incidence; Lipopeptides; Male; Micafungin; Microbial Sensitivity Tests; Sequence Analysis, DNA; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Triazoles; Voriconazole

2017
A multi-centric Study of Candida bloodstream infection in Lima-Callao, Peru: Species distribution, antifungal resistance and clinical outcomes.
    PloS one, 2017, Volume: 12, Issue:4

    Topics: Adolescent; Adult; Aged; Amphotericin B; Anidulafungin; Antifungal Agents; Candida; Candidemia; Child; Child, Preschool; Drug Resistance, Fungal; Echinocandins; Female; Fluconazole; Humans; Incidence; Infant; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Peru; Prospective Studies; Triazoles; Voriconazole; Young Adult

2017
Pharmacoeconomic analysis of antifungal therapy for primary treatment of invasive candidiasis caused by Candida albicans and non-albicans Candida species.
    BMC infectious diseases, 2017, 07-10, Volume: 17, Issue:1

    Topics: Anidulafungin; Antifungal Agents; Candida; Candida albicans; Candidemia; Candidiasis, Invasive; Caspofungin; Cost-Benefit Analysis; Echinocandins; Economics, Pharmaceutical; Fluconazole; Humans; Lipopeptides; Micafungin; Taiwan; Treatment Outcome

2017
Filter Adsorption of Anidulafungin to a Polysulfone-Based Hemofilter During CVVHD In Vitro.
    Artificial organs, 2018, Volume: 42, Issue:2

    Topics: Acute Kidney Injury; Adsorption; Anidulafungin; Antifungal Agents; Candidemia; Critical Illness; Dialysis Solutions; Echinocandins; Humans; Kidney Failure, Chronic; Polymers; Renal Dialysis; Sulfones

2018
Comparative study of Candida spp. isolates: Identification and echinocandin susceptibility in isolates obtained from blood cultures in 15 hospitals in Medellín, Colombia.
    Journal of global antimicrobial resistance, 2018, Volume: 13

    Topics: Anidulafungin; Antifungal Agents; Blood Culture; Candida; Candidemia; Caspofungin; Colombia; Disk Diffusion Antimicrobial Tests; Echinocandins; Genes, rRNA; High-Throughput Nucleotide Sequencing; Hospitals; Humans; Microbial Sensitivity Tests; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

2018
Delay in effective therapy in anidulafungin-resistant Candida tropicalis fungaemia: Potential for rapid prediction of antifungal resistance with whole-genome-sequencing.
    Journal of global antimicrobial resistance, 2019, Volume: 16

    Topics: Anidulafungin; Antifungal Agents; Candida tropicalis; Candidemia; Drug Resistance, Fungal; Genome, Fungal; Humans; Microbial Sensitivity Tests; Mutation; Whole Genome Sequencing

2019
Species distribution and antifungal drug susceptibilities of yeasts isolated from the blood samples of patients with candidemia.
    Scientific reports, 2019, 03-07, Volume: 9, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amphotericin B; Anidulafungin; Antifungal Agents; Candida; Candida albicans; Candida glabrata; Candida parapsilosis; Candidemia; Caspofungin; Child; Child, Preschool; Female; Fluconazole; Flucytosine; Humans; Itraconazole; Male; Micafungin; Microbial Sensitivity Tests; Middle Aged; Triazoles; Voriconazole; Young Adult

2019
Species-specific and drug-specific differences in susceptibility of Candida biofilms to echinocandins: characterization of less common bloodstream isolates.
    Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:6

    Topics: Anidulafungin; Antifungal Agents; Biofilms; Candida; Candida albicans; Candidemia; Caspofungin; Echinocandins; Humans; Lipopeptides; Micafungin; Microbial Sensitivity Tests; Plankton; Species Specificity

2013
Cost-effectiveness of anidulafungin in confirmed candidaemia and other invasive Candida infections in Spain.
    Journal de mycologie medicale, 2013, Volume: 23, Issue:3

    Topics: Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Cost-Benefit Analysis; Echinocandins; Health Care Costs; Humans; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Spain

2013
Pharmacokinetics of anidulafungin in two critically ill patients with septic shock undergoing CVVH.
    Journal of chemotherapy (Florence, Italy), 2013, Volume: 25, Issue:6

    Topics: Aged; Anidulafungin; Antifungal Agents; Area Under Curve; Candidemia; Critical Illness; Echinocandins; Female; Hemofiltration; Humans; Male; Middle Aged; Shock, Septic

2013
Role of FKS Mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:8

    Topics: Anidulafungin; Antifungal Agents; Candida glabrata; Candidemia; Caspofungin; Drug Resistance, Multiple, Fungal; Echinocandins; Fluconazole; Fungal Proteins; Glucosyltransferases; Lipopeptides; Micafungin; Microbial Sensitivity Tests; Mutation; United States

2014
Candidemia in the intensive care unit: analysis of direct treatment costs and clinical outcome in patients treated with echinocandins or fluconazole.
    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2015, Volume: 34, Issue:2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anidulafungin; Antifungal Agents; Candidemia; Caspofungin; Child; Child, Preschool; Echinocandins; Female; Fluconazole; Health Care Costs; Hospitalization; Humans; Infant; Intensive Care Units; Lipopeptides; Male; Micafungin; Middle Aged; Treatment Outcome; Young Adult

2015
Comparison of the probability of target attainment of anidulafungin against Candida spp. in patients with acute leukaemia.
    International journal of antimicrobial agents, 2014, Volume: 44, Issue:5

    Topics: Anidulafungin; Antifungal Agents; Candidemia; Echinocandins; Humans; Leukemia; Microbial Sensitivity Tests; Plasma; Time Factors

2014
Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis.
    BMC infectious diseases, 2015, Oct-26, Volume: 15

    Topics: Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Caspofungin; Cost-Benefit Analysis; Drug Costs; Echinocandins; Fluconazole; Humans; Intensive Care Units; Length of Stay; Lipopeptides; Micafungin; Models, Economic; Treatment Outcome; United Kingdom

2015
Susceptibility of Candida albicans biofilms to caspofungin and anidulafungin is not affected by metabolic activity or biomass production.
    Medical mycology, 2016, Volume: 54, Issue:2

    Topics: Anidulafungin; Antifungal Agents; Biofilms; Biomass; Candida albicans; Candidemia; Caspofungin; Echinocandins; Gentian Violet; Humans; Lipopeptides; Micafungin; Microbial Sensitivity Tests; Microscopy, Electron, Scanning; Oxidation-Reduction; Portugal; Staining and Labeling; Tetrazolium Salts

2016
First isolation of Candida wangnamkhiaoensis from the blood of immunocompromised paediatric patient.
    Mycoses, 2016, Volume: 59, Issue:11

    Topics: Anidulafungin; Antifungal Agents; Candida; Candidemia; Caspofungin; Child, Preschool; DNA, Ribosomal Spacer; Echinocandins; Fluconazole; Humans; Hyphae; Immunocompromised Host; Lipopeptides; Male; Phylogeny; Polymerase Chain Reaction; Sequence Alignment; Voriconazole

2016
First report of Candida auris in America: Clinical and microbiological aspects of 18 episodes of candidemia.
    The Journal of infection, 2016, Volume: 73, Issue:4

    Topics: Adult; Aged; Americas; Amphotericin B; Amplified Fragment Length Polymorphism Analysis; Anidulafungin; Antifungal Agents; Azoles; Candida; Candidemia; Cross Infection; Disease Outbreaks; DNA, Fungal; Drug Resistance, Fungal; Echinocandins; Female; Humans; Infant, Newborn; Male; Microbial Sensitivity Tests; Venezuela; Young Adult

2016
Frequency of the Paradoxical Effect Measured Using the EUCAST Procedure with Micafungin, Anidulafungin, and Caspofungin against Candida Species Isolates Causing Candidemia.
    Antimicrobial agents and chemotherapy, 2017, Volume: 61, Issue:1

    Topics: Anidulafungin; Antifungal Agents; Candida; Candida tropicalis; Candidemia; Candidiasis; Caspofungin; Echinocandins; Lipopeptides; Micafungin; Microbial Sensitivity Tests

2017
Characterization of Candida parapsilosis complex isolates.
    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2011, Volume: 17, Issue:3

    Topics: Amphotericin B; Anidulafungin; Antifungal Agents; Biofilms; Candida; Candidemia; Drug Resistance, Fungal; Echinocandins; Humans; Microbial Sensitivity Tests; Pyrimidines; Random Amplified Polymorphic DNA Technique; Triazoles; Voriconazole

2011
[Prevalence of Candida parapsilosis, C. orthopsilosis and C. metapsilosis in candidemia over a 5-year period at Nantes hospital and in vitro susceptibility to three echinocandins by E-test®].
    Pathologie-biologie, 2011, Volume: 59, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anidulafungin; Antifungal Agents; Candida; Candidemia; Caspofungin; Child; Child, Preschool; Drug Resistance, Fungal; Echinocandins; Female; France; Fungal Proteins; Glycosyltransferases; Hospitals, University; Humans; In Vitro Techniques; Infant; Infant, Newborn; Lipopeptides; Male; Micafungin; Microbial Sensitivity Tests; Middle Aged; Prevalence; Retrospective Studies; Ribotyping; Species Specificity; Young Adult

2011
Clinical experience of anidulafungin for the treatment of patients with documented candidemia.
    Journal of chemotherapy (Florence, Italy), 2010, Volume: 22, Issue:6

    Topics: Anidulafungin; Antifungal Agents; Candida; Candidemia; Catheters, Indwelling; Cross Infection; Echinocandins; Female; Fluconazole; Humans; Italy; Male; Middle Aged; Pyrimidines; Retrospective Studies; Treatment Outcome; Triazoles; Voriconazole

2010
Resource utilization and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patients.
    PharmacoEconomics, 2011, Volume: 29, Issue:8

    Topics: Adult; Aged; Anidulafungin; Antifungal Agents; Candidemia; Candidiasis, Invasive; Clinical Trials, Phase III as Topic; Critical Illness; Double-Blind Method; Drug Costs; Echinocandins; Female; Fluconazole; Health Resources; Hospital Costs; Hospitalization; Humans; Intensive Care Units; Length of Stay; Male; Middle Aged; Randomized Controlled Trials as Topic; Regression Analysis; Retrospective Studies

2011
Efficacy of anidulafungin against biofilms of different Candida species in long-term trials of continuous flow cultivation.
    Mycoses, 2011, Volume: 54, Issue:6

    Topics: Aerobiosis; Anaerobiosis; Anidulafungin; Antifungal Agents; Biofilms; Candida; Candidemia; Echinocandins; Humans; Microbial Sensitivity Tests; Pyrimidines; Triazoles; Voriconazole

2011
Austrian clinical practice with anidulafungin in 2008: a multicenter survey.
    Journal of chemotherapy (Florence, Italy), 2011, Volume: 23, Issue:5

    Topics: Anidulafungin; Antifungal Agents; Austria; Candida; Candidemia; Candidiasis; Candidiasis, Invasive; Comorbidity; Echinocandins; Female; Humans; Male; Medical Records; Practice Patterns, Physicians'; Retrospective Studies; Risk Factors; Severity of Illness Index; Time Factors

2011
Population pharmacokinetic-pharmacodynamic analysis of anidulafungin in adult patients with fungal infections.
    Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anidulafungin; Antifungal Agents; Area Under Curve; Body Weight; Candida; Candidemia; Candidiasis, Invasive; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Echinocandins; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Randomized Controlled Trials as Topic; Treatment Outcome

2013